Your Methodology Adoption Dies at the Deal Review, Not at the Rollout
Methodology stalls not because reps don't know it, but because managers don't inspect it in the right place at the right moment.
Six weeks after a methodology rollout, behaviour has reverted. Reps are back to selling on relationship and hope. Qualification fields in the CRM are populated with fiction. The enablement team is already drafting a "reinforcement programme." And nobody has named the actual cause, which is that the deal review never changed.
The rollout is visible. There is a kick-off, a certification, a slide deck with the framework on it, possibly a laminated card. The deal review is invisible. It happens weekly, it is run by whoever the manager happens to be, and in most organisations it has silently evolved into a forecast call with a few extra slides. Stage, amount, close date, "what do you need from me?" Next deal. That cadence will undo any methodology investment you make, because it never tests whether the rep is actually applying the framework to a live, contested deal where it matters.
That is the failure point. Not the rollout. Not the certification pass rate. The deal review.
Why the Deal Review Is the Only Moment That Counts
Methodology certification tells you a rep can answer questions about a framework in a low-stakes, prepared context. It tells you nothing about whether they can operate the framework on a deal where the prospect is evasive, the internal champion has gone quiet, and the close date is three weeks away.
The deal review is the only recurring moment where a manager can apply real pressure to a live deal and find out whether the rep is genuinely qualified or just narratively qualified. There is a difference. Narratively qualified means the rep has a story. Genuinely qualified means the rep has evidence, specific evidence, that maps to the framework's criteria.
Most managers never create that pressure because they are measuring the wrong thing. They are measuring stage progression and forecast category. Those are outputs. The methodology is supposed to govern the inputs that make those outputs reliable. If you never inspect the inputs, you have no idea whether the forecast is built on anything real.
What a Bad Deal Review Sounds Like
A manager asks: "Where are we on Acme?"
The rep says: "It's looking good. We've got a champion, they're moving it through procurement, close date is end of month."
The manager says: "Great. What do you need from me?"
Every word of that exchange is methodology-free. "Looking good" is sentiment. "We've got a champion" is assertion. "Moving it through procurement" tells you nothing about whether there is actual internal mobilisation or just one optimistic contact copying in a procurement email address. This is a conversation between two people who have agreed not to test each other, and it happens in companies with fully certified MEDDIC programmes every single day.
The Restructured Deal Review: What to Actually Do
This is not complicated, but it requires the manager to be willing to ask questions the rep might not be able to answer. That discomfort is the point.
Step one: pick the deal on deal quality, not deal size.
Most managers review the biggest deals or the ones the rep volunteers. Review the deals where you suspect the qualification is weakest. The deal the rep hasn't mentioned lately. The one that has been in the same stage for six weeks.
Step two: start from the qualification layer, not the timeline.
Do not ask "where are we?" Ask the question that forces the rep to prove each qualification element. Below is a working structure for a MEDDIC-based review.
| Qualification Element | Question to Ask | What Inability to Answer Tells You |
|---|---|---|
| Metrics | "What specific business outcome is the economic buyer accountable for, and what is the quantified gap our solution closes?" | Rep has not done ROI work with a credible stakeholder |
| Economic Buyer | "Have you spoken directly to the EB in the last three weeks? What did they say about priority?" | Rep is selling below the line and hoping it escalates |
| Decision Criteria | "What are their top three evaluation criteria, in their words?" | Rep is projecting criteria rather than uncovering them |
| Decision Process | "Walk me through every step between here and a signed order, including who approves at each gate." | Rep does not understand the actual buying process |
| Identify Pain | "What is the consequence of doing nothing? Who in their organisation is feeling it most?" | Pain is surface-level; urgency is manufactured |
| Champion | "What has your champion done internally to advance this? What have they risked for this deal?" | Rep has a contact, not a champion |
For MEDDPICC, add Paper Process and Competition. The structure is the same: ask for evidence, not assertion.
Step three: diagnose, do not perform.
When the rep cannot answer, the instinct is to fill the silence with advice. Resist it. The gap in the answer is diagnostic information. A rep who cannot articulate the decision process is in a different situation from a rep who cannot articulate the economic buyer's metrics. The coaching required is different. The deal risk is different.
Note which elements the rep could not evidence. Do that consistently across your team and you will quickly see whether the skill gap is individual, systematic across the team, or concentrated in specific framework elements. That is the data your enablement programme should be built on. Right now, most enablement programmes are built on certification scores, which measure recall under no pressure.
A Stalled Deal Diagnosis Card: Which MEDDIC Element Is Broken? is useful at this stage, particularly if your managers are new to evidence-based inspection and need a prompt card to stop them drifting back to timeline questions.
Step four: close the loop with the CRM.
After the review, the rep should update the relevant qualification fields. Not as an administrative task, but as the written record of what was evidenced. If the champion field says "Sarah, VP Ops" but the rep could not describe a single action Sarah has taken internally, the field is wrong. Update it.
The CRM Stage-to-MEDDIC Field Mapping Template can help RevOps align field labels to framework elements so this step is not an afterthought.
What Your Certification Pass Rate Is Actually Measuring
A 94% methodology certification rate means 94% of your reps could answer questions about MEDDIC in a workshop environment with preparation time. It is a measure of training completion dressed up as a measure of capability. If you ran those same reps through a structured deal review on a live opportunity with no notice, what would you find?
That question is worth sitting with. The Methodology Certification Validity Audit: Is Your Pass Rate Real? exists precisely because most sales organisations have never formally asked it.
The Manager Behaviour Is the Programme
Everything above is contingent on the manager actually doing it. You can issue a new deal review template, run a manager enablement session, put the qualification fields in the CRM. None of it persists if managers revert to forecast-call behaviour the moment they are busy or the quarter is tight.
The deal review has to be the place where methodology lives or it lives nowhere. That means manager behaviour is the adoption programme, not the rollout. You can assess rep skill all day, but if the manager running the review has not internalised the framework well enough to ask hard questions under real conditions, the rep has no mirror to hold themselves against.
Inspect the inspectors. That is the part most methodology programmes skip, because it is uncomfortable, and because the people running the programme usually report to the people who need inspecting.
If the deal reviews in your organisation are still running as forecast calls, your methodology certification is decorative. The framework exists on paper, in a SharePoint folder, and in the memory of a kick-off that most of the team has already forgotten. Fix the deal review first. Everything else follows from that.